Patrys Receives R&D Tax Incentive Refund
0
Patrys has today announced that its wholly-owned subsidiary Nucleus Therapeutics Pty Ltd has received a rebate of $1.285 million for…
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30…
PAT-DX1 GMP specification testing update
Patrys’ Contract Development Manufacturing Organisation (CDMO) advised the Company that specification testing using a revised process is still not complete,…
Patrys FY24 Annual Report
Patrys has released its Annual Report for the 2023-2024 Financial Year (FY24). Highlights include: Data from preclinical studies with PAT-DX1…
PAT-DX1 GMP manufacturing run update
Patrys’ Contract Development Manufacturing Organisation (CDMO) advised the Company that it has identified an inconsistency with one of the processes…
Quarterly Activities Report and 4C Quarterly Cash Flow Report – quarter ended 30 June 2024
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30…
Update on GMP manufacturing run of PAT-DX1
Patrys’ Contract Development Manufacturing Organization (CDMO) has advised that its specification testing for the drug substance produced in the recent…
Quarterly Activities Report and 4C Quarterly Cash Flow Report – quarter ended 31 March 2024
Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31…
Positive preclinical data for deoxymabs in vasculitis
Patrys has announced that new data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease…
Potential to use Deoxymabs to treat autoimmune diseases
Patrys has announced that new data from preclinical studies using PAT-DX1 in animal models of anti neutrophil cytoplasmic antibody (ANCA)…